Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSMED Inc officer William Lewis reported a proposed sale of 3,223 common shares, with an aggregate market value of $561,349 and an approximate sale date of January 8, 2026. The shares were acquired from the issuer through stock plan activity on January 6, 2026. Earlier sales listed were 2,357 shares on January 7, 4,096 shares on January 6, and 10,699 shares each on December 18 and December 4, 2025.
Insmed Inc. officer Roger Adsett reported a proposed sale of 802 common shares, with an aggregate market value of $140,406 and an approximate sale date of January 7, 2026. Adsett acquired 802 shares through stock plan activity on January 5, 2026. The notice also reports his sale of 1,429 common shares on January 6, 2026, for gross proceeds of $247,688.
An insider has filed a Rule 144 notice to sell 709 shares of common stock through broker Merrill Lynch on or about 01/07/2026, to be traded on NASDAQ. These 709 shares were acquired on 01/05/2026 through stock plan activity with the issuer. The notice also lists prior sales over the last three months by the same seller, including 1,396 common shares sold on 01/06/2026 for gross proceeds of 241968, and 27,130 common shares sold on 11/03/2025 for gross proceeds of 4985054. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer.
A company insider filed a Rule 144 notice to sell 2357 shares of common stock through Merrill Lynch on the NASDAQ, with an approximate sale date of 01/07/2026. These 2357 shares of common stock were acquired on 01/05/2026 through stock plan activity from the issuer.
Over the past three months, the same seller, William Lewis, has already sold additional common shares of the issuer. These sales included 4096 shares on 01/06/2026 for gross proceeds of 709959, and two earlier sales of 10699 shares each on 12/18/2025 and 12/04/2025 for gross proceeds of 1786437 and 2199583, respectively.
An insider has filed a notice to sell 1,678 common shares of the issuer through Merrill Lynch on or about 01/07/2026 on the NASDAQ. The filing lists an aggregate market value of 293,935 for these planned sales, compared with 213,273,469 shares outstanding for the issuer.
The shares to be sold were acquired on 01/05/2026 as stock plan activity from the issuer. The notice also discloses that Sara Bonstein sold 1,517 common shares on 01/06/2026, generating gross proceeds of 262,941 over the past three months.
INSMED Inc officer Martina Flammer filed notice of a proposed sale of 1,434 common shares, with an aggregate market value of $252,154 and an approximate sale date of January 7, 2026. Merrill Lynch is listed as the broker. The notice also lists four prior sales: 10,185 shares for gross proceeds of $1,770,153 on January 6, 2026; 12,303 shares for $2,108,459 on January 5, 2026; 8,895 shares for $1,840,841 on December 1, 2025; and 31,226 shares for $5,921,820 on November 11, 2025.
Insmed Inc. filed a notice of proposed insider sale under Rule 144. The filing covers planned sales of 1,517 shares of common stock through Merrill Lynch, with an aggregate market value of $262,941. These shares are part of a class with 213,273,469 shares outstanding and are expected to be sold on or about 01/06/2026 on the NASDAQ exchange. The seller acquired the 1,517 common shares on 01/04/2026 through stock plan activity directly from the issuer, with the payment also dated 01/04/2026 and described as stock plan related ("n/a" for cash nature of payment).
Insmed has a shareholder planning to sell 1,429 shares of its common stock under a Form 144 notice. The sale is expected to be executed through Merrill Lynch in Washington, DC, with an aggregate market value of 247,688 and is targeted for 01/06/2026 on NASDAQ.
The shares to be sold were acquired on 01/04/2026 through stock plan activity from the issuer, with payment made on the same date. The filing also notes that 213,273,469 shares of the issuer’s securities were outstanding, providing context for the planned sale.
Insmed Inc. (INSM) reported a planned sale of company stock under Rule 144. A holder intends to sell 1,396 shares of common stock through Merrill Lynch on or about 01/06/2026 on the NASDAQ market, with an aggregate market value of $241,968.68 based on the figures shown. These shares were acquired from the issuer on 01/04/2026 through stock plan activity, with the same date listed as the payment date.
The notice also reports that during the past three months, Michael Smith sold 27,130 common shares on 11/03/2025 for gross proceeds of $4,985,054. The filing lists 213,273,469 common shares outstanding for the issuer, providing context for the size of the planned transaction.
A shareholder filed a Form 144 indicating an intent to sell 4,096 shares of common stock through Merrill Lynch on or about 01/06/2026, with the stock listed on NASDAQ. These shares were acquired on 01/04/2026 through stock plan activity from the issuer, with the same date listed as the payment date. The filing notes that common shares outstanding were 213,273,469, providing a baseline for the company’s share count.
Over the prior three months, the same seller, William Lewis, reported two additional sales of common stock: 10,699 shares on 12/18/2025 for gross proceeds of 1,786,437, and another 10,699 shares on 12/04/2025 for gross proceeds of 2,199,583. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.